Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 537-539

  Onujiogu, N ^a   Lengyel, E ^a   Yamada, S D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cisplatin; Intraperitoneal; Leukoencephalopathy; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; METOPROLOL; PACLITAXEL;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; MENTAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; PACLITAXEL; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 56449115592     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.032     Document Type: Article

References (11)

1. Allen J.A., Adlakha A., and Bergethon P.R. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI Regimen for metastatic colon cancer. Arch Neurol 63 (2006) 1475-1478
2. Kaito E., Terae S., Kobayashi R., Kudo K., Tha K.K., and Miyasaka K. The role of tumor lysis in reversible posterior leukoencephalopathy syndrome. Pediatr Radiol 35 (2005) 722-727
3. Ito Y., Arahata Y., Goto Y., Hirayama M., Nagamutsu M., Yasuda T., et al. Cisplatin neurotoxicity presenting as reversible posterior leukoenephalopathy syndrome. Am J Neurorad 19 (1998) 415-417
4. Bakshi R., Shaikh Z.A., Bates V.E., and Kinkel P.R. Thrombotic thrombocytopenic purpura: brain CT and MRI findings in 12 patients. Neurol 52 (1999) 1285-1288
5. Sontia B., and Touyz R.M. Role of magnesium in hypertension. Arch Biochem Biophys 458 (2007) 33-39
6. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al., Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 354 (2006) 34-43
7. Howell S.B., Pfeifle C.L., Wung W.E., Olshen R.A., Lucas W.E., Yon J.L., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97 (1982) 845-851
8. Icli F., Karaoguz H., Dincol D., Demirkazik A., Gunel N., Karaoguz R., et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 72 (1993) 587-593
9. Ziske C.G., Schottker B., Gorschluter M., Mey U., Kleinschmidt R., Schlegel U., et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 13 (2002) 629-631
10. Perry J.R., and Warner E. Transient encephalopathy after paclitaxel infusion. Neurology 46 (1996) 1596-1599
11. Glantz M.J., Choy H., Kearns C.M., Mills P.C., Wahlerg L.U., Zuhowski E.G., et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87 (1995) 1077-1081